Ranbaxy faces increased regulatory vigilance
This article was originally published in Scrip
Ranbaxynow faces increased regulatory vigilance across the world after the US FDAissued warning letters for good manufacturing practice (GMP) deviations at the company's Indian plants in Paonta Sahib and Dewas. The FDA had issued an import alert for about 30 of Ranbaxy's products citing GMP concerns.
You may also be interested in...
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.